Online inquiry

IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5631MR)

This product GTTS-WQ5631MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5631MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2811MR IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG-301
GTTS-WQ6755MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DS-1062
GTTS-WQ3032MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ7911MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GSK3196165
GTTS-WQ11500MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MetMAb
GTTS-WQ8163MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA HL036337
GTTS-WQ8297MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HM-12525A
GTTS-WQ464MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 3G3
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW